Company news
Tvardi Therapeutics, Inc. news in 2023
Tvardi Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis
December 17, 2023
Cara Therapeutics Reports Third Quarter 2023 Financial Results
November 12, 2023
Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty
November 1, 2023
Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023
October 22, 2023
Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients
September 24, 2023
Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 4, 2023
Cara Therapeutics Reports Second Quarter 2023 Financial Results
August 6, 2023
Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors
August 2, 2023
Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
August 1, 2023
Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023
July 23, 2023
Cara Therapeutics to Present at the Jefferies Healthcare Conference
May 31, 2023
Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
May 17, 2023
Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
May 17, 2023
Cara Therapeutics Reports First Quarter 2023 Financial Results
May 14, 2023
Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023
April 30, 2023
Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
April 9, 2023
Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report
March 13, 2023
Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
March 5, 2023
Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
February 20, 2023
Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine
February 7, 2023
Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023
January 16, 2023
Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
January 2, 2023